Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.13 USD | -2.36% | -2.13% | -24.91% |
Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 36.81M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.23
x | P/E ratio 2025 * |
-3.23
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.85% |
Latest transcript on Marker Therapeutics, Inc.
1 day | -2.36% | ||
1 week | -2.13% | ||
Current month | +1.98% | ||
1 month | -14.85% | ||
3 months | -2.59% | ||
6 months | +51.56% | ||
Current year | -24.91% |
Managers | Title | Age | Since |
---|---|---|---|
Juan F. Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 18-10-16 | |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 4.13 | -2.36% | 5,953 |
24-05-09 | 4.23 | -0.94% | 11,530 |
24-05-08 | 4.27 | +6.22% | 10,227 |
24-05-07 | 4.02 | -2.19% | 13,477 |
24-05-06 | 4.11 | -2.61% | 13,065 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.91% | 36.81M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- MRKR Stock